1. Cytotoxicity of diethyldithiocarbamate in human versus rodent cell lines

   • Justin D. Cohen
   • H. Ian Robins

   Preclinical Studies Pages: 137 - 142

2. In vitro activity of 4′ -iodo-4′ -deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay

   • Raffaella Villa
   • Nadia Zaffaroni
   • Rosella Silvestrini

   Preclinical Studies Pages: 143 - 144

3. Antitumor effect of GPA1734 in rat Walker 256 carcinoma

   • Eleftheria Missirlis
   • George Karakiulakis
   • Michael E. Maragoudakis

   Preclinical Studies Pages: 145 - 147

4. In vivo and in vitro pharmacokinetics of 4,6-benzylidene-D-glucose (BG) in rats

   • John M. Dornish
   • Rolf O. Larsen
   • Erik O. Pettersen

   Preclinical Studies Pages: 149 - 157

5. A phase I and pharmacokinetic study of trimetrexate using a 24-hour continuous-infection schedule

   • Carmen J. Allegra
   • Jean Jenkins
   • Gregory A. Curt

   Clinical Studies Pages: 159 - 166

6. Phase I evaluation of diaziquone in childhood cancer

   • J. M. Falletta
   • B. Cushing
   • R. A. Krance

   Clinical Studies Pages: 167 - 170

7. Phase I trial of tallysomycin S_10b, a bleomycin analogue

   • Frank P. Paolozzi
   • Robert C. Gaver
   • Robert L. Comis

   Clinical Studies Pages: 171 - 180

8. Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas

   • Frank M. Balis
   • Andrea Gillespie
   • David G. Poplack

   Preclinical Studies Pages: 181 - 182

9. Phase II study of n-methylformamide (NSC 3051) and spirogermanium (NSC 192965) in the treatment of advanced small cell lung cancer

   • David S. Ettinger
   • Dianne M. Finkelstein
   • John C. Ruckdeschel

   Clinical Studies Pages: 183 - 185

10. Phase II trial of carboplatin in patients with advanced melanoma

    • Ephraim S. Casper
    • Dean Bajorin

    Clinical Studies Pages: 187 - 190

11. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced epithelial ovarian cancer

    • William P. McGuire III
    • John A. Blessing
    • Alan Munoz

    Clinical Studies Pages: 191 - 194

12. Phase II study of N-methylformamide (N-MF) (NSC 3051) in patients with advanced squamous cancer of the cervix

    • William P. McGuire III
    • John A. Blessing
    • Michael L. Berman

    Clinical Studies Pages: 195 - 197

13. Phase II study of Fludarabine Phosphate in multiple myeloma

    • Eric H. Kraut
    • John J. Crowley
    • Sydney E. Salmon

    Preclinal Studies Pages: 199 - 200

14. Evaluation of carboplatin (NSC 241240) in patients with recurrent or metastatic renal cell carcinoma

    • Donald L. Trump
    • Paul Elson

    Clinical Studies Pages: 201 - 203

15. 5-Day vinblastine infusion for pancreatic adenocarcinoma

    • Jerry T. Guy
    • Thomas Fleming
    • James F. Boyd

    Clinical Studies Pages: 205 - 206

16. Pirarubicin (4′-o-tetrahydropyranil-adriamycin) for treatment of advanced breast cancer

    • Werner Scheithauer
    • Helmut Samonigg
    • Heinz Ludwig

    Clinical Studies Pages: 207 - 210

17. Hypersensitivity reactions to trimetrexate

    • Jean L. Grem
    • Susan A. King
    • Thomas D. Brown

    Clinical Studies Pages: 211 - 214

18. Ifosfamide and mesna in combination with other cytostatic drugs in the treatment of patients with advanced cancer

    • Geoffrey Falkson
    • Martin R. Chasen
    • Hendrè C. Falkson

    Clinical Studies Pages: 215 - 219

19. Clinical cardiotoxicity of esorubicin (4′-deoxydoxorubicin,DxDx): Prospective studies with serial gated heart scans and reports of selected cases

    • Q. Scott Ringenberg
    • Kathleen J. Propert
    • Mark Green

    Clinical Studies Pages: 221 - 226

20. Clinical toxicity associated with tiazofurin

    • Jean L. Grem
    • Larry Rubinstein
    • Dale D. Shoemaker

    Clinical Studies Pages: 227 - 238